19.05.2021
As part of the Lunch & Learn event series of the Biotechnologieverbund Berlin-Brandenburg (bbb), Dr. Ahmed Sheriff presented the PentraSorb® CRP and reported on its use at Klinikum Havelhöhe, where almost all COVID-19 patients are now treated with CRP apheresis. Afterwards there was an exciting discussion.
18.05.2021
ZDF has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
07.05.2021
In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.
The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.
22.04.2021
An article by ntv Wissen reported on the use of CRP apheresis in COVID-19 patients at the Gemeinschaftskrankenhaus Havelhöhe.
You can read the article in German here .
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.
17.04.2021
COVID-19 patients are treated with CRP apheresis at the Klinikum Havelhöhe. This was featured in the rbb Abendschau.
07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.
20.03.2021
Pentracor organizes a Care Symposium about CRP apheresis at the 13th ISFA & E-ISFA Congress.
30.03.2021
The Brandenburg business magazine FORUM reported on CRP apheresis in its April 2021 issue.
11.03.2021
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
